Cosmos Health (COSM)
Distributes health products through Greek pharmacies while manufacturing and marketing proprietary healthcare brands.
Something off on this page? Send us feedback.
Distributes pharmaceutical and health products mainly through Greek pharmacy networks, while Cana manufactures for the group and third parties and Sky Premium Life and Mediterranation supply owned brands. Wholesale provides most revenue, making the business financially concentrated in Greece.
Distributes pharmaceuticals, parapharmaceuticals, medical devices, cosmetics, and supplements through Cosmofarm to Greek pharmacies, while Decahedron performs licensed generic and OTC wholesale in the United Kingdom. Wholesale supplies most revenue, tying results closely to Greek pharmacy demand and the lower-margin economics of pharmaceutical distribution.
Manufactures pharmaceuticals, nutraceuticals, cosmetics, biocides, and medical devices at Cana for its own portfolio and third parties. Markets proprietary Sky Premium Life and Mediterranation products alongside other healthcare brands, linking sourcing, distribution, owned products, and manufacturing within one group.
Uses Cloudscreen for AI-assisted drug-repurposing predictions and in-vitro validation support, with disclosed candidates still in development rather than established commercial product lines. Manufacturing and product activities remain subject to extensive government regulation, while drug candidates must progress through preclinical work, clinical trials, regulatory review, and commercialization.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.8M · Total debt $16.0M · Total assets $61.5M · Shareholders' equity $20.7M
- Revenue
- $19.0M
- Operating income
- −$2.9M
- Net income
- −$6.1M
No dividends on record.
| Institutions | 3.87% | 2.11M shares | |
|---|---|---|---|
| 21 holders · as of Jun 30, 2026 | |||
| Insiders | 32.09% | 17.47M shares | |
| 7 holders · as of Jul 31, 2026 | |||
| Other | 64.04% | 34.85M shares | |
| remainder | |||
54.43M company shares as of Aug 27, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Grigorios SiokasInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 26.82% | 14.60M | filed Jul 31, 2026 |
Georgios TerzisInsiderofficer: Chief Financial Officer | 4.71% | 2.56M | filed Jul 30, 2026 |
UBS Group AGInstitution | 1.09% | 594,462 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.61% | 333,842 | as of Jun 30, 2026 |
Jane Street Group, LLCInstitution | 0.53% | 289,287 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 30, 2026 | Grigorios Siokas | director, 10 percent owner, officer: Chief Executive Officer | +349,825 | $0.2001 |
| Jul 29, 2026 | Grigorios Siokas | director, 10 percent owner, officer: Chief Executive Officer | +766,284 | $0.1827 |
| Jun 16, 2026 | Georgios Terzis | officer: Chief Financial Officer | +168,135 | $0.2498 |
| Jun 10, 2026 | Grigorios Siokas | director, 10 percent owner, officer: Chief Executive Officer | +701,447 | $0.2281 |
| Jun 11, 2026 | Grigorios Siokas | director, 10 percent owner, officer: Chief Executive Officer | +218,447 | $0.2060 |
